Product Description
Mechanisms of Action: ENaC Activator
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Inhalant,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Apeptico Forschung und Entwicklung
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, China, Germany
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Hyperphosphatemia
Phase 2: Acute Respiratory Distress Syndrome|Pulmonary Edema
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AP301-II-002 | P2 |
Recruiting |
Acute Respiratory Distress Syndrome |
2024-12-01 |
35% |
| AP301-PD-01 | P1 |
Completed |
Healthy Volunteers |
2024-02-08 |
|
| 2017-003855-47 | P2 |
Active, not recruiting |
Acute Respiratory Distress Syndrome|Pulmonary Edema |
2023-01-24 |
|
| CTR20231624 | P3 |
Not yet recruiting |
Hyperphosphatemia |
None |